Search - tctmd.com

Displaying 161 - 180 of 1055

Sort: Relevancy | Date

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News EuroPCR 2019

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

Caitlin E. Cox

May 23, 2019

News Conference News EuroPCR 2019

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

L.A. McKeown

May 22, 2019

News Conference News EuroPCR 2019

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

Caitlin E. Cox

May 21, 2019

Presentation EuroPCR 2019

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Presenter: Clemens von Birgelen

May 21, 2019

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Daily News

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

Michael O'Riordan

May 02, 2019

News Daily News

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Michael O'Riordan

April 30, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

CABG vs PCI in Left Main Disease: The Debate Continues

Yael L. Maxwell

March 12, 2019

News Conference News CRT 2019

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

Yael L. Maxwell

March 07, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Michael O'Riordan

February 22, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

Presentation JIM 2019

Unmet Clinical Needs With Current Drug-Eluting Stents

Presenter: Davide Capodanno

February 14, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

Advertisement

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Firehawk Stent Still Holds Up Well to Xience at 2 Years: TARGET All Comers

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

3-year clinical outcome following treatment with thin, very thin or ultrathin strut drug-eluting stents in small coronary vessels in BIO-RESORT

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

CABG vs PCI in Left Main Disease: The Debate Continues

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

Unmet Clinical Needs With Current Drug-Eluting Stents

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content